Table 2.
Grade II–IV Acute GvHD by Day 100
| Variable | Cumulative Incidence | Multivariable | ||||||
|---|---|---|---|---|---|---|---|---|
| N | Estimate (%) |
95% CI | P-value | RR | 95% CI | P-value | ||
| MMF | <0.01 | |||||||
| 2g | 93 | 63 | 52–75 | 1.0 | ||||
| 3g | 175 | 43 | 35–51 | 0.51 | 0.36–0.72 | <0.01 | ||
| Age | 0.01 | -- | -- | -- | ||||
| 18–34 years | 26 | 46 | 26–66 | |||||
| 35–59 years | 176 | 57 | 49–65 | |||||
| 60+ years | 66 | 33 | 22–45 | |||||
| Gender | 0.85 | -- | -- | -- | ||||
| Male | 163 | 50 | 42–59 | |||||
| Female | 105 | 50 | 39–60 | |||||
| Year of HCT | <0.01 | -- | -- | -- | ||||
| 2000–2005 | 96 | 64 | 52–75 | |||||
| 2006–2012 | 172 | 42 | 33–50 | |||||
| HLA disparity | 0.89 | -- | -- | -- | ||||
| 4/6 | 155 | 49 | 41–57 | |||||
| 5/6 | 97 | 52 | 41–62 | |||||
| 6/6 | 16 | 50 | 24–76 | |||||
| Disease risk | 0.65 | -- | -- | -- | ||||
| Standard risk | 126 | 49 | 40–59 | |||||
| High-risk | 142 | 51 | 42–60 | |||||
| HCT-CI | 0.82 | -- | -- | -- | ||||
| 0 | 67 | 54 | 41–67 | |||||
| 1–2 | 66 | 50 | 37–63 | |||||
| ≥3 | 129 | 47 | 37–56 | |||||
| Female donor to male recipient | 0.94 | -- | -- | -- | ||||
| Yes | 141 | 50 | 41–59 | |||||
| No | 127 | 50 | 40–59 | |||||
| CMV serostatus | 0.78 | -- | -- | -- | ||||
| Positive | 110 | 51 | 41–61 | |||||
| Negative | 158 | 49 | 41–58 | |||||
| ATG | 0.06 | |||||||
| No | 182 | 54 | 46–62 | 1.0 | ||||
| Yes | 86 | 41 | 30–52 | 0.60 | 0.41–0.88 | 0.01 | ||